A.P. Pharma Inc., of Redwood City, Calif., appointed Robert Zerbe to its board.
Access Pharmaceuticals Inc., of Dallas, appointed Stuart Duty to its board.
Amylin Pharmaceuticals Inc., of San Diego, elected Thomas Testman to its board.
Avera Pharmaceuticals Inc., of San Diego, named Alison Pilgrim chief medical officer.
Bio-Technology General Corp., of East Brunswick, N.J., appointed Whitney Stearns senior vice president, chief financial officer and treasurer.
Chronogen Inc., of Montreal, added Jan Vijg to its scientific advisory board.
Dey LP, of Napa, Calif., appointed Al Erario vice president of quality systems.
Drug Development Resources Inc., of Boston, added Daniel Madden as vice president of software solutions.
Genome Prairie, of Calgary, Alberta, appointed Gijs van Rooijen chief scientific officer.
Illumina Inc., of San Diego, appointed Tristan Orpin vice president of worldwide sales.
Intronn Inc., of Rockville, Md., appointed Gary Temple director of cancer biology and Nancy Streicher corporate controller.
ISTA Pharmaceuticals Inc., of Irvine, Calif., appointed Kathleen LaPorte, Liza Nelson and Peter Hutt to its board.
Oxxon Pharmaccines Ltd., of Oxford, UK, formed a scientific advisory board, consisting of Adrian Hill as chairman, Leszek Borysiewicz, Wayne Koff, Andrew McMichael, Howard Thomas and Jeffrey Weber.
Peninsula Pharmaceuticals Inc., of Fremont, Calif., named Matthew Wikler chief medical officer.
Pozen Inc., of Chapel Hill, N.C., appointed Kenneth Lee to its board.
Ricerca Biosciences LLC, of Concord, Ohio, appointed Ronald Brandt executive vice president of marketing and sales.
Serologicals Corp., of Atlanta, elected Ronald Gelbman to its board.
Sonus Pharmaceuticals Inc., of Bothell, Wash., added Paul Weiden as director of clinical oncology.
Sprout Group, of New York, appointed Paul Sekhri as partner for healthcare technology investments.
Sunesis Pharmaceuticals Inc., of South San Francisco, elected Lester Mitscher to its scientific advisory board.
TargeGen Inc., of San Diego, appointed David Ranney to its scientific advisory board.
TopoTarget Prolifix A/S, of Copenhagen, Denmark, appointed Leif Ham chief financial officer.